On September 12, 2022, Cara Therapeutics, Inc. announced the appointment of Ryan Maynard to serve as Chief Financial Officer of the Company, effective September 12, 2022. In Mr. Maynard, 53, has over 20 years of experience in leading finance organizations at both public and private biopharmaceutical companies. Mr. Maynard served most recently as the Chief Financial Officer of LetsGetChecked, a global healthcare solutions company, from October 2019 to March 2022.

Mr. Maynard previously was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company, from February 2018 to June 2019. From 2001 through December 2017, Mr. Maynard held various leadership roles at Rigel Pharmaceuticals, a public commercial-stage drug development company, including serving as Executive Vice President and Chief Financial Officer from 2007 through December 2017. During his tenure at Rigel, Mr. Maynard was a key member of the executive team that successfully discovered, developed, and launched Tavalisse for the treatment of chronic immune thrombocytopenia.

Mr. Maynard started his career at Ernst & Young, LLP where he earned his CPA. Mr. Maynard has been a member of the Board of Directors of Iovance Biotherapeutics since 2015. Mr. Maynard earned his B.S. in Commerce – Accounting from Santa Clara University.